ID   Walvax-2
AC   CVCL_5J50
SY   WALVAX-2; WALVAX 2; Walvax 2; WALVAX2; Walvax2
DR   CCRID; 4201PAT-CCTCC00374
DR   Wikidata; Q54993580
RX   Patent=CN102911910A;
RX   Patent=CN103525770B;
RX   PubMed=25803132;
RX   PubMed=26116706;
CC   Group: Patented cell line.
CC   Group: Vaccine production cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201055.
CC   Senescence: Maintains excellent capabilities for growth and proliferation until PDL 50 (maximum PDL is 58).
CC   Doubling time: 39-41 hours (Note=At 28th passage), 40-42 hours (Note=At 38th passage), 57-62 hours (Note=At 48th passage) (PubMed=25803132).
CC   Anecdotal: Is causing an outrage in some pro-lifer circles because it is a cell line originating from an aborted (for medical reasons) 3-month old female fetus.
CC   Derived from site: In situ; Fetal lung; UBERON=UBERON_0005597.
CC   Cell type: Fibroblast of lung; CL=CL_0002553.
ST   Source(s): PubMed=25803132; PubMed=26116706
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D12S391: 19,22
ST   D13S317: 11,12
ST   D16S539: 9,12
ST   D18S51: 15,18
ST   D19S433: 13.2,14.2
ST   D21S11: 29,30
ST   D2S1338: 20,25
ST   D3S1358: 15,16
ST   D5S818: 10,11
ST   D6S1043: 14,19
ST   D7S820: 8,12
ST   D8S1179: 13,15
ST   FGA: 21,24
ST   Penta D: 10,11
ST   Penta E: 5,18
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 18
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   3FM
CA   Finite cell line
DT   Created: 14-12-15; Last updated: 29-06-23; Version: 18
//
RX   Patent=CN102911910A;
RA   Huang Z., He L.-F., Zhang W., Ma B., Wang L.-L.,
RA   Zhao Q.-Y., Zhang Y., Wu W.-J., Chen M., Wang X., Tang Y.-F.;
RT   "Human embryo lung fibroblast strain and method for using human embryo
RT   lung fibroblast strain for producing hand-foot-mouth viral vaccine.";
RL   Patent number CN102911910A, 06-Feb-2013.
//
RX   Patent=CN103525770B;
RA   Ma B., Yang Z., He L.-F., Wang L.-L., Chen M., Wang X.;
RT   "Application of human fetal lung fibroblast line in preparation of
RT   hepatitis A vaccines.";
RL   Patent number CN103525770B, 19-Aug-2015.
//
RX   PubMed=25803132; DOI=10.1080/21645515.2015.1009811;
RA   Ma B., He L.-F., Zhang Y.-L., Chen M., Wang L.-L., Yang H.-W., Yan T.,
RA   Sun M.-X., Zheng C.-Y.;
RT   "Characteristics and viral propagation properties of a new human
RT   diploid cell line, Walvax-2, and its suitability as a candidate cell
RT   substrate for vaccine production.";
RL   Hum. Vaccin. Immunother. 11:998-1009(2015).
//
RX   PubMed=26116706; DOI=10.1096/fj.14-266718;
RA   Ye F., Chen C.-G., Qin J., Liu J., Zheng C.-Y.;
RT   "Genetic profiling reveals an alarming rate of cross-contamination
RT   among human cell lines used in China.";
RL   FASEB J. 29:4268-4272(2015).
//